Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT02559622
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 894
- Registration Number
- NCT02555683
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
Phase 4
Completed
- Conditions
- Acute Heart Failure
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 887
- Registration Number
- NCT02554890
- Locations
- 🇺🇸
Novartis Investigative Site, Wausau, Wisconsin, United States
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2216
- Registration Number
- NCT02554786
- Locations
- 🇬🇧
Novartis Investigative Site, Wiltshire, United Kingdom
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Not Applicable
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive (COPD)
- Interventions
- Other: Patient preference questionnaire
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT02551224
- Locations
- 🇦🇷
Novartis Investigative Site, Ciudad Autonoma de Bs As, Argentina
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 136
- Registration Number
- NCT02550106
- Locations
- 🇫🇷
Novartis Investigative Site, Vandoeuvre Les Nancy, France
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT02546674
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT02547714
- Locations
- 🇯🇵
Novartis Investigative Site, Shinjuku-Ku, Tokyo, Japan
Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos
Phase 1
Terminated
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02543086
- Locations
- 🇦🇺
Novartis Investigative Site, Brisbane, Queensland, Australia
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02534909
- Locations
- 🇱🇹
Novartis Investigative Site, Vilnius, Lithuania